Connect with us

Start Ups

Early outpatient treatment with hydroxychloroquine is the most effective for treatment of COVID-19, Dr. Harvey Risch of Yale University says




Early outpatient treatment is the most effective for treatment of coronavirus patients, according to a new study published in American Journal of Epidemiology. The study, which was led by Dr. Harvey A Risch of Yale University, suggests that late stage studies missed the point about effective usage of hydroxychloroquine. Dr. Risch says immediate and early ramping-up of treatment for high-risk COVID-19 patients is key to controlling the coronavirus pandemic crisis.

We’ve learned a lot about the virus since coronavirus started in Wuhan, China in December 2019. To date, more than 4,498,343 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality.

According to the study, Dr. Risch said an outpatient treatment that prevents hospitalization is desperately needed. “Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September,” Dr. Risch  said.

In a 29-page report, the study suggests that early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease.

Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000

The great majority of infected people are at low risk for progression or will manifest the infection asymptomatically. For the rest, outpatient treatment is required that prevents disease progression and hospitalization. Exposures will occur as isolation policies are lifted and people begin to mix, even with various degrees of public isolation such as mask usage and physical separation still in place. Thus, the key to returning society toward normal functioning and to preventing huge loss of life, especially among older individuals, people with comorbidities, African Americans and Hispanics and Latinos, is a safe, effective and proactive outpatient treatment that prevents ORIGINAL hospitalization in the first place.

In reviewing the current evidence, Dr. Risch said this:

Based on laboratory and other preliminary evidence to-date, among many others, two candidate medication regimens have been widely discussed for outpatient treatment: remdesivir (Gilead Sciences, Inc., Foster City, California), and hydroxychloroquine (HCQ) plus azithromycin (AZ). Remdesivir has been studied extensively in laboratory work and in animals (8) and for other viral diseases and has good biological properties, suggesting utility for SARSCoV-2 infection. In a study of remdesivir compassionate use in 53 hospitalized patients with severe disease (9), 13% died, which appears lower than what might have been expected without treatment, though greater than the deaths in the placebo arm of the Adaptive COVID-19 Treatment Trial (more below).

Dr. Risch went on to talk about hydroxychloroquine and said this:

The other suggestion is the combined regimen of HCQ+AZ (or its variant HCQ+doxycycline). The FDA has recently issued guidance (15) to physicians and the general public advising that the combination HCQ+AZ should not generally be used except by critically ill hospital inpatients or in the context of registered clinical trials. The NIH panel for Covid-19 treatment guidelines say essentially the same (16), and a similar statement has been released by the major cardiology societies (17). Numerous reviews of HCQ efficacy and adverse events have been and continue to be published. To my knowledge, all of these reviews have omitted the two critical aspects of reasoning about these drugs: use of HCQ combined with AZ or with doxycycline, and use in the outpatient setting. For example, the Veterans’ Administration Medical Centers study (18) examined treated hospitalized patients and was fatally flawed (19).  The same point about outpatient use of the combined medications has been raised by a panel of distinguished French physicians (20) in petitioning their national government to allow outpatient use of HCQ+AZ. It appears that the FDA, NIH and cardiology society positions have been based upon theoretical calculations about potential adverse events and from measured physiologic changes rather than from current real-world mortality experience with these medications and that their positions should be revised.

In reviewing all available evidence about hydroxychloroquine, Dr. Risch said this:

In reviewing all available evidence, I will show that HCQ+AZ and HCQ+doxycycline are generally safe for short-term use in the early treatment of most symptomatic high-risk outpatients, where not contraindicated, and that they are
effective in preventing hospitalization for the overwhelming majority of such patients. If these combined medications become standard-of-care, they are likely to save an enormous number of lives that would otherwise be lost to this endemic disease.

Dr. Risch concluded with the following:

I conclude that HCQ+AZ and HCQ+doxycycline, preferably with zinc (47) can be this outpatient treatment, at least until we find or add something better, whether that could be remdesivir or something else. It is our obligation not to stand by, just “carefully watching,” as the old and infirm and inner city of us are killed by this disease and our economy is destroyed by it and we have nothing to offer except high-mortality hospital treatment. We have a solution, imperfect, to attempt to deal with the disease. We have to let physicians employing good clinical judgement use it and informed patients choose it. There is a small chance that it may not work. But the urgency demands that we at least start to take that risk and evaluate what happens, and if our situation does not improve we can stop it, but we will know that we did everything that we could instead of sitting by and letting hundreds of thousands die because we did not have the courage to act according to our rational calculations.

“Americans now dying each week. These medications need to be widely available and promoted immediately for physicians to prescribe,” the study concludes.

The full report can be found at Oxford University Press website


Start Ups

Messaging Software Startup Aampe Raises Rs 13 Crore From Sequoia India Surge




  • Aampe is a Singapore-based startup that embeds experiments within routine messaging to turn consumer communication into a business growth engine.
  • The startup will use the funding for product development to serve global customers.

Singapore-based personalized messaging software startup Aampe has raised $1.8 million (or about Rs 13.2 crore) in funding led by Sequoia India scale-up program Sequoia India Surge.

The startup with fresh funding plans to accelerate its growth momentum and product development to serve the customers globally.

Last week, US-based venture capital firm Sequoia Capital had announced the names of 17 startups, including Aampe, Kyt, Pagarbook, Plum, among others.

The selected startups received a total of $45 million in their financing rounds from Sequoia Surge and other investors.

From the last few months, Sequoia scale-up program is actively investing in startups from industries, including edtech, fintech, consumer tech, health tech, developer tools, B2B marketplaces, and tech for small and medium-sized enterprises.

Commenting on the development, Paul Meinshausen, Co-founder, Aampe, said, “As a data scientist, I’ve struggled repeatedly across multiple companies with the quality of tools for user messaging. Naive automation has been prioritized over reliable inference and quality data generation. We’re building Aampe to make first-class data science serve one of the most important responsibilities of any business: speaking and listening to customers,”

Also Read: Kalpathi Group Enters Edtech Space, Launches Veranda Learning

“While this is true to some extent, the usefulness of data also degrades quickly — and many companies underestimate the importance of continuously generating new and high-quality data. Aampe’s APIs do this and feed that data back into product development at both strategic and tactical levels,” he added.

Founded in July 2020, by Sami Abboud, Schaun Wheeler, and Paul Meinshausen. Aampe uses machine learning to personalize messages and communication for customers, helping businesses drive better customer retention and growth.

Since its inception, Aampe has acquired customers across Asia, including India, Singapore, Myanmar, and Indonesia.

The startup helps product managers to unlock the power of data and continuous experimentation to deliver the business value.

Aiming for seamless integration, Aampe’s APIs, and reinforcement learning pipelines and models can be easily plugged into messaging and communication providers that companies already use. This allows product managers, data scientists, and growth marketers to avoid expensive and time-intensive engineering projects. 

Aampe also has its offices in Antwerp (Belgium) and Raleigh (USA).

with inputs from PTI (Press Trust Of India)

Follow IndianStartupNews on FacebookInstagramTwitter for the latest updates from the startup ecosystem.


Continue Reading

Start Ups

Tata inches closer to make foray into Online Grocery Biz




Unless something really goes bad, Tata Group should be making an official foray into the online grocery biz by as early as next week. Sources privy to the matter claim that salt-to-steel conglomerate has almost closed on buying nearly 80% stake in BigBasket for $1.3 Bn. The deal reportedly values India’s largest online grocery store at almost $1.6 Bn.

According to several news reports, the Tata Group will acquire existing investors’ stake, which comes to around 50-60%. Additionally, the Mumbai based corporate giant will buy 20-30% new shares of BigBasket. This will take Tata’s stake in the company to 80%.

A pie chart showing the stake of existing investors in BigBasket

How BigBasket Benefits from Tata Acquisition deal   

With Tata likely to become a majority stakeholder in BigBasket once the deal is officially signed, the latter will be in a much more commanding position to take on JioMart. What the Tata Group eventually brings for BigBasket is the funding muscle as well as the reputation of a large conglomerate and deep experience in scaling the business.

Probably no one could have matched Reliance’s funding prowess than the Tatas.

BigBasket in Numbers:

  • Revenue & Losses in Fy20: Revenue = Rs 5,200 Cr & Losses = Rs 902 Cr
  • Revenue & Losses in Fy19: Revenue = Rs 3,200 Cr & Losses = Rs 348 Cr
  • Daily Orders: 3,00,000
  • GMV: $1 Bn

How Tatas will benefit from BigBasket Acquisition Deal  

With BigBasket acquisition deal, Tatas will get a massive market share in India’s online grocery Biz in one shot. The deal is also likely to become a launch pad for Tatas to foray into the e commerce biz in a big way. This foray is likely to happen through a super app, which is likely to be launched once the company seals the BigBasket.

With this super app, Tatas are aiming to dabble into the burgeoning e-commerce sector.

Sources claim that Tatas are sniffing a serious growth in the e-commerce in the post-Covid scenario.


Continue Reading

Start Ups

Genesis Therapeutics raises $52M A round for its AI-focused drug discovery mission




Sifting through the trillions of molecules out there that might have powerful medicinal effects is a daunting task, but the solution biotech has found is to work smarter, not harder. Genesis Therapeutics has a new simulation approach and cross-disciplinary team that has clearly made an impression: the company just raised a $52 million A round.

Genesis competed in the Startup Battlefield at Disrupt last year, impressing judges with its potential, and obviously others saw it as well — in particular Rock Springs Capital, which led the round.

Over the last few years many companies have been formed in the drug discovery space, powered by increased computing and simulation power that lets them determine the potential of molecules in treating certain diseases. At least that’s the theory. The reality is a bit messier, and while these companies can narrow the search, they can’t just say “here, a cure for Parkinson’s.”

Founder Evan Feinberg got into the field when an illness he inherited made traditional lab work, as an intern at a big pharma company, difficult for him. The computational side of the field, however, was more accessible and ended up absorbing him entirely.

He had dabbled in the area before and arrived at what he feels is a breakthrough in how molecules are represented digitally. Machine learning has, of course, accelerated work in many fields, biochemistry among them, but he felt that the potential of the technology had not been tapped.

“I think initially the attempts were to kind of cut and paste deep learning techniques, and represent molecules a lot like images, and classify them — like you’d say, this is a cat picture or this is not a cat picture,” he explained in an interview. “We represent the molecules more naturally: as graphs. A set of nodes or vertices, those are atoms, and things that connect them, those are bonds. But we’re representing them not just as bond or no bond, but with multiple contact types between atoms, spatial distances, more complex features.”

The resulting representation is richer and more complex, a more complete picture of a molecule than you’d get from its chemical formula or a stick diagram showing the different structures and bonds. Because in the world of biochemistry, nothing is as simple as a diagram. Every molecule exists as a complicated, shifting 3D shape or conformation where important aspects like the distance between two carbon formations or bonding sites is subject to many factors. Genesis attempts to model as many of those factors as it can.

“Step one is the representation,” he said, “but the logical next step is, how does one leverage that representation to learn a function that takes an input and outputs a number, like binding affinity or solubility, or a vector that predicts multiple properties at once?”

That’s the work they’ve focused on as a company — not just creating a better model molecule, but being able to put a theoretical molecule into simulation and say, it will do this, it won’t do this, it has this quality but not that one.

Some of this work may be done in partnerships, such as the one Genesis has struck up with Genentech, but the teams could very well find drug candidates independent of those, and for that reason the company is also establishing an internal development process.

The $52M infusion ought to do a lot to push that forward, Feinberg wrote in an email:

“These funds allow us to execute on a number of critical objectives, most importantly further pioneering AI technologies for drug development and advancing our therapeutics pipeline. We will be hiring more top notch AI researchers, software engineers, medicinal chemists and biotech talent, as well as building our own research labs.”

Other companies are doing simulations as well and barking up the same tree, but Feinberg says Genesis has at least two legs up on them, despite the competition raising hundreds of millions and existing for years.

“We’re the only company in the space that’s working at the intersection of modern deep neural network approaches and biophysical simulation — conformational change of ligands and proteins,” he said. “And we’re bringing this super technical platform to experts who have taken FDA-approved drugs to market. We’ve seen tremendous value creation just from that — the chemists inform the AI too.”

The recent breakthrough of AlphaFold, which is performing the complex task of simulation protein folding far faster than any previous system, is as exciting to Feinberg as to everyone else in the field.

“As scientists, we are incredibly excited by recent progress in protein structure prediction. It is an important basic science advance that will ultimately have important downstream benefits to the development of novel therapeutics,” he wrote. “Since our Dynamic PotentialNet technology is unique in how it leverages 3D structural information of proteins, computational protein folding — similar to recent progress in cryo-EM — is a nice complementary tailwind for the Genesis AI Platform. We applaud all efforts to make protein structure more accessible such that therapeutics can be more easily developed for patients of all conditions.”

Also participating in the funding round were T. Rowe Price Associates, Andreessen Horowitz (who led the seed round), Menlo Ventures, and Radical Ventures.


Continue Reading


Facial recognition tech: risks, regulations and future startup opportunities in the EU




Facial recognition differs from the conventional camara surveillance, as it is not a mere passive recording, but rather it entails identification of an individual by comparing newly capture images with those images saved in a data base.

The status in Europe

Although facial recognition is not yet specifically regulated in Europe, it is covered by the General Data Privacy Regulation – GDPR – as a means of collecting and processing personal biometric data, including facial data and fingerprints. Therefore, facial recognition is only possible under the criteria of the GDPR.

Biometric data provides a high level of accuracy when identifying an individual due to the uniqueness of the identifiers (facial image or fingerprint) and a great potential to improve business security.

The processing of biometric data, which is considered sensitive data, is in principle prohibited with some exceptions, such as, for reasons of substantial public interests, to protect the vital interest of the data holder or another person, or if data holder has given its explicit consent, to name some.

Moreover, other factors such as proportionality or power imbalance are considered to determine if it is a valid exception, for instance, facial recognition can be considered disproportionate to track attendance in a school, since less intrusive options are available. Also even when the data holder has explicitly consented to the processing of biometric data, consideration should be given to potential imbalance of power dynamics between the individual data holder and the institution processing the data. For instance in a student and school scenario, there could be doubts as to whether the consent of the parents of a student to the use of facial recognition techniques, is freely given in the manner intended by the GDPR and therefore, a valid exception to the prohibition of processing.

One of the challenges in this field is that the underlying technology used for facial recognition, for instance AI, can present serious risks of bias and discrimination, affecting and discriminating many people without the social control mechanism that governs human behaviour. Bias and discrimination are inherent risks of any societal or economic activity. Human decision-making is not immune to mistakes and biases. However, the same bias when present in AI could have a much larger effect.

Authentication vs. identification

Obviously biometrics for authentication (which is described as a security mechanism), is not the same as remote biometric identification (which is used for instance in airports or public spaces, to identify multiple persons’ identities at a distance and in continuous manner by checking them against data stored in a database).

The collection and use of biometric information used for facial recognition and identification in public spaces carries specific risks for fundamental rights. In fact, the European Commission (EC) has warned that remote biometric identification is the most intrusive form of facial recognition and it is in principle prohibited in Europe.

So where is all this going?

What should prevail: the protection of fundamental rights, or the advancement that comes with invasive and overpowering new technologies?

New technologies, like AI, bring some benefits, such as technological advancement and more efficiency and economic growth, but at what cost?

Using a risk-based approach the EC has considered the use of AI for remote biometric identification and other intrusive surveillance technologies to be high-risk, since it could compromise fundamental rights such as human dignity, non-discrimination and privacy protection.

The EU Commission is currently investigating whether additional safeguards are needed or whether facial recognition should not be allowed in certain cases, or certain areas, opening the door for a debate regarding the scenarios that could justify the use of facial recognition for remote biometric identification.

Artificial intelligence entails great benefits but also several potential risks, such as opaque decision-making, gender-based or other kinds of discrimination, intrusion in our private lives or being used for criminal purposes.

To address these challenges, the Commission in its white paper on AI, issued in February this year, has proposed a new regulatory framework on high risk AI, and a prior conformity assessment, including testing and certification of AI facial recognition high risk systems to ensure that they abide by EU standards and requirements.

The regulatory framework will include additional mandatory legal requirements related to training data, record-keeping, transparency, accuracy, oversight and application-based use, and specific requirements for some AI applications, specifically those designed for remote biometric facial recognition.

We should then expect new regulation coming, with the aim to have an AI system framework, compliant with current legislation and that does not compromise fundamental rights.

Opportunities for startups?

Facial recognition technologies are here to stay, therefore, so if you are thinking about changing your hair colour, watch out as your phone might not recognize you! With the speed in which facial recognition is growing, we should not wait too long for new forms of ‘selfie payment’.

Facial recognition is already been used quite successfully in several areas, among them:

  1. Health: Where thanks to face analysis is already possible to track patience use of mediation more accurately;
  2. Market and retail: Where facial recognition promises the most, as ‘knowing your customer’ is a hot topic, this means placing cameras in retail outlets to analyze the shopper behavior and improve the customer experience, subject of course to the corresponding privacy checks; and,
  3. Security and law enforcement: That is, to find missing children, identify and track criminals or accelerate investigations.

With lots of choices on the horizon for facial recognition, it remains to be seen whether European startups will lead new innnovations in this area.


Continue Reading
Cleantech1 hour ago

Four Corners EV Charging: Utah & Colorado Are Leaving NM & Arizona Behind

Cleantech1 hour ago

Aptera Announces First “Never Charge” Electric Vehicle

Cleantech2 hours ago

Gayam Motor Works & Sokowatch Launch East Africa’s First Commercial Electric Tuk-Tuks

Cleantech2 hours ago

The German Constitution May Protect A Right To Human Driving

Cleantech3 hours ago

2021 Toyota RAV4 Prime Fails Moose Avoidance Test

SaaS4 hours ago

Top 10 SaaStr Videos of the Week: MongoDB, Splash, Slack + Yammer, Gainsight and More!

Cleantech4 hours ago

Supercell Technology From Cadenza Is Centerpiece Of New York Energy Storage Project — CleanTechnica Exclusive (Video)

SaaS4 hours ago

How to Create PPC Campaigns for Real Estate Marketing

Cleantech5 hours ago

Cleantech ETFs Vastly Outperform Dow Jones, Oil & Gas In 2020

Cleantech5 hours ago

ICE Racing Can Still Teach Us Things

Cleantech5 hours ago

California’s Low Carbon Fuel Standard Accelerating Transportation Electrification

SaaS6 hours ago

7 Warning Signs You Have Product Flop on Your Hands (and How to Fix It!)

Ecommerce6 hours ago

Amazon Marketing Consulting

Globe NewsWire6 hours ago

McPhy Energy : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 novembre 2020

Cleantech7 hours ago

Breaking News! Oakland & Seattle Ban Natural Gas as Cities Continue to Lead on Electrification

SaaS7 hours ago

Did You Ship At Least 3 Game-Changing Features This Year?

SaaS8 hours ago

When Should You Use Microsites

Globe NewsWire9 hours ago

Dassault Aviation : Roll-out du Falcon 6X

Globe NewsWire9 hours ago

Dassault Aviation: Falcon 6X rollout

Energy11 hours ago

Crescent Point Announces 2021 Budget

Energy11 hours ago

PHNIX dévoile une nouvelle pompe à chaleur pour le chauffage, le refroidissement et l’eau chaude des habitations, destinée au marché européen

Energy11 hours ago

PHNIX stellt neue Wärmepumpe für Hausheizung, Kühlung und Warmwasser für den europäischen Zielmarkt vor

Esports11 hours ago

NiP announce “Path of a Ninja” talent program

Energy11 hours ago

Wilbur-Ellis Agribusiness Acquires Probe Schedule

Energy11 hours ago

High Purity Alumina Market Estimated to Expand at a CAGR of 12.5% over the Forecast Period of 2020 to 2030 – Persistence Market Research

Energy14 hours ago

Gunvor inaugura una nueva línea de crédito de 540 millones de dólares dedicada al biodiésel

Energy14 hours ago

Gunvor Launches New US $540 Million Biodiesel Borrowing Base

Techcrunch15 hours ago

China’s internet regulator takes aim at forced data collection

Blockchain16 hours ago

Amazing Blocks joins startup and innovation hub TechQuartier

Blockchain16 hours ago

Amazing Blocks attended the European Blockchain Convention